Altimmune to Present at the Cachexia Regulatory & Trials Update Workshop of the 17th International Conference of the Society on Sarcopenia, Cachexia & Wasting Disorders
Details for the panel discussion are as follows:
| Title: | Muscle Wasting in Weight Loss Therapy |
| Session: | Treatment Approaches to Address Muscle Wasting in the Context of Obesity Therapy & Regulatory Issues |
| Presenter: | |
| Date/Time: |
About Altimmune
Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH. For more information, please visit www.altimmune.com.
Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter
Company Contact:
Chief Financial Officer
Phone: 240-654-1450
ir@altimmune.com
Investor Contact:
Phone: 646-382-3403
lroth@burnsmc.com
Media Contact:
Inizio Evoke, Biotech
Phone: 619-826-4657
Danielle.cantey@inizioevoke.com
This press release was published by a CLEAR® Verified individual.
Source: Altimmune, Inc
